1-May-2026
Avita Medical Names Cary Vance Permanent CEO, Reshapes Board
TipRanks (Fri, 1-May 6:16 PM ET)
AVITA Medical appoints Cary Vance as permanent CEO
Seeking Alpha News (Thu, 30-Apr 9:26 AM ET)
AVITA Medical Names Cary Vance as Chief Executive Officer
Globe Newswire (Thu, 30-Apr 8:50 AM ET)
Globe Newswire (Wed, 29-Apr 4:05 PM ET)
AVITA Medical to Announce First Quarter 2026 Financial Results
Globe Newswire (Thu, 23-Apr 4:10 PM ET)
Globe Newswire (Tue, 21-Apr 4:30 PM ET)
Globe Newswire (Wed, 15-Apr 9:20 AM ET)
Globe Newswire (Tue, 14-Apr 7:45 AM ET)
Globe Newswire (Wed, 8-Apr 4:10 PM ET)
AVITA Medical Showcases Acute Burn and Wound Care Portfolio at ABA 2026, Featuring New Cohealyx Data
Globe Newswire (Tue, 7-Apr 4:10 PM ET)
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
Avita Medical trades on the NASDAQ stock market under the symbol RCEL.
As of May 1, 2026, RCEL stock price climbed to $4.44 with 145,661 million shares trading.
RCEL has a beta of 0.96, meaning it tends to be less sensitive to market movements. RCEL has a correlation of 0.03 to the broad based SPY ETF.
RCEL has a market cap of $136.65 million. This is considered a Micro Cap stock.
Last quarter Avita Medical reported $18 million in Revenue and -$.38 earnings per share. This fell short of revenue expectation by $-8 million and exceeded earnings estimates by $.09.
In the last 3 years, RCEL traded as high as $21.70 and as low as $3.22.
The top ETF exchange traded funds that RCEL belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
RCEL has underperformed the market in the last year with a price return of -52.5% while the SPY ETF gained +30.4%. RCEL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +0.7% and -13.6%, respectively, while the SPY returned +4.4% and +1.5%, respectively.
RCEL support price is $4.08 and resistance is $4.56 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RCEL shares will trade within this expected range on the day.